Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ricrolin is a sterile ophthalmic drug formulation containing riboflavin (vitamin B2) at a concentration of 0.1%, used as eye drops for corneal collagen cross-linking (CXL) procedures in the treatment of keratoconus and secondary corneal ectasias[3][5]. The mechanism involves riboflavin acting as a photosensitizer that, upon activation by ultraviolet A (UVA) light, generates reactive oxygen species leading to the formation of new covalent bonds between collagen fibers in the cornea. This process increases biomechanical stability and halts disease progression[3]. Specialized formulations such as Ricrolin Plus are designed for enhanced penetration using iontophoresis-assisted delivery through an intact epithelium[1][4][6]. The product is intended exclusively for external ocular use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ricrolin.